What is the current valuation of the Benign Prostatic Hyperplasia Treatment Market?

The market valuation was 12.45 USD Billion in 2024. Read More

What is the projected market size for the market by 2035?

The market is projected to reach 22.44 USD Billion by 2035. Read More

What is the expected CAGR for the market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 5.5%. Read More

Which therapeutic classes are leading in the Benign Prostatic Hyperplasia Treatment Market?

Alpha Blockers and 5-Alpha Reductase Inhibitors are leading therapeutic classes, with valuations of 6.73 and 4.52 USD Billion respectively by 2035. Read More

What are the projected revenues for Mono Drug Therapy and Combination Drug Therapy by 2035?

Both Mono Drug Therapy and Combination Drug Therapy are projected to reach 11.22 USD Billion by 2035. Read More

Who are the key players in the market?

Key players include Astellas Pharma, Boehringer Ingelheim, Eli Lilly and Company, and others. Read More

How do the revenues of Alpha Blockers compare to Phosphodiesterase-5 Inhibitors by 2035?

By 2035, Alpha Blockers are expected to generate 6.73 USD Billion, while Phosphodiesterase-5 Inhibitors are projected at 3.38 USD Billion. Read More

What is the growth potential for the 'Others' segment in the market?

The 'Others' segment is projected to grow to 7.81 USD Billion by 2035. Read More

What role do major pharmaceutical companies play in the market dynamics?

Companies like Merck & Co. and Pfizer Inc. are likely to influence market dynamics through innovation and strategic partnerships. Read More

How does the market's growth trajectory appear for the next decade?

The market's growth trajectory appears robust, with a projected increase from 12.45 USD Billion in 2024 to 22.44 USD Billion by 2035. Read More

Benign Prostatic Hyperplasia Treatment Market

ID: MRFR/HC/10317-HCR

128 Pages

Vikita Thakur

Last Updated: April 06, 2026

Benign Prostatic Hyperplasia Treatment Market Research Report: Size, Share, Trend Analysis By Therapeutic Class (Alpha Blockers, 5- Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others), By Therapy (Mono Drug Therapy and Combination Drug Therapy), and By Region (North America, Europe, Asia-Pacific, and Rest Of The World) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Methodology Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Therapeutic Class (USD Billion)
  1. 4.1.1 Alpha Blockers
  2. 4.1.2 5- Alpha Reductase Inhibitors
  3. 4.1.3 Phosphodiesterase-5 Inhibitors
  4. 4.1.4 Others
2. 4.2 Healthcare, BY Therapy (USD Billion)
  1. 4.2.1 Mono Drug Therapy
  2. 4.2.2 Combination Drug Therapy
3. 4.3 Healthcare, BY Region (USD Billion)
  1. 4.3.1 North America
    1. 4.3.1.1 US
    2. 4.3.1.2 Canada
  2. 4.3.2 Europe
    1. 4.3.2.1 Germany
    2. 4.3.2.2 UK
    3. 4.3.2.3 France
    4. 4.3.2.4 Russia
    5. 4.3.2.5 Italy
    6. 4.3.2.6 Spain
    7. 4.3.2.7 Rest of Europe
  3. 4.3.3 APAC
    1. 4.3.3.1 China
    2. 4.3.3.2 India
    3. 4.3.3.3 Japan
    4. 4.3.3.4 South Korea
    5. 4.3.3.5 Malaysia
    6. 4.3.3.6 Thailand
    7. 4.3.3.7 Indonesia
    8. 4.3.3.8 Rest of APAC
  4. 4.3.4 South America
    1. 4.3.4.1 Brazil
    2. 4.3.4.2 Mexico
    3. 4.3.4.3 Argentina
    4. 4.3.4.4 Rest of South America
  5. 4.3.5 MEA
    1. 4.3.5.1 GCC Countries
    2. 4.3.5.2 South Africa
    3. 4.3.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Astellas Pharma (JP)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Boehringer Ingelheim (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Eli Lilly and Company (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 GlaxoSmithKline (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Merck & Co. (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Pfizer Inc. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sanofi (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Teva Pharmaceutical Industries (IL)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 AbbVie Inc. (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY THERAPEUTIC CLASS
4. 6.4 US MARKET ANALYSIS BY THERAPY
5. 6.5 CANADA MARKET ANALYSIS BY THERAPEUTIC CLASS
6. 6.6 CANADA MARKET ANALYSIS BY THERAPY
7. 6.7 EUROPE MARKET ANALYSIS
8. 6.8 GERMANY MARKET ANALYSIS BY THERAPEUTIC CLASS
9. 6.9 GERMANY MARKET ANALYSIS BY THERAPY
10. 6.10 UK MARKET ANALYSIS BY THERAPEUTIC CLASS
11. 6.11 UK MARKET ANALYSIS BY THERAPY
12. 6.12 FRANCE MARKET ANALYSIS BY THERAPEUTIC CLASS
13. 6.13 FRANCE MARKET ANALYSIS BY THERAPY
14. 6.14 RUSSIA MARKET ANALYSIS BY THERAPEUTIC CLASS
15. 6.15 RUSSIA MARKET ANALYSIS BY THERAPY
16. 6.16 ITALY MARKET ANALYSIS BY THERAPEUTIC CLASS
17. 6.17 ITALY MARKET ANALYSIS BY THERAPY
18. 6.18 SPAIN MARKET ANALYSIS BY THERAPEUTIC CLASS
19. 6.19 SPAIN MARKET ANALYSIS BY THERAPY
20. 6.20 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC CLASS
21. 6.21 REST OF EUROPE MARKET ANALYSIS BY THERAPY
22. 6.22 APAC MARKET ANALYSIS
23. 6.23 CHINA MARKET ANALYSIS BY THERAPEUTIC CLASS
24. 6.24 CHINA MARKET ANALYSIS BY THERAPY
25. 6.25 INDIA MARKET ANALYSIS BY THERAPEUTIC CLASS
26. 6.26 INDIA MARKET ANALYSIS BY THERAPY
27. 6.27 JAPAN MARKET ANALYSIS BY THERAPEUTIC CLASS
28. 6.28 JAPAN MARKET ANALYSIS BY THERAPY
29. 6.29 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC CLASS
30. 6.30 SOUTH KOREA MARKET ANALYSIS BY THERAPY
31. 6.31 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC CLASS
32. 6.32 MALAYSIA MARKET ANALYSIS BY THERAPY
33. 6.33 THAILAND MARKET ANALYSIS BY THERAPEUTIC CLASS
34. 6.34 THAILAND MARKET ANALYSIS BY THERAPY
35. 6.35 INDONESIA MARKET ANALYSIS BY THERAPEUTIC CLASS
36. 6.36 INDONESIA MARKET ANALYSIS BY THERAPY
37. 6.37 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC CLASS
38. 6.38 REST OF APAC MARKET ANALYSIS BY THERAPY
39. 6.39 SOUTH AMERICA MARKET ANALYSIS
40. 6.40 BRAZIL MARKET ANALYSIS BY THERAPEUTIC CLASS
41. 6.41 BRAZIL MARKET ANALYSIS BY THERAPY
42. 6.42 MEXICO MARKET ANALYSIS BY THERAPEUTIC CLASS
43. 6.43 MEXICO MARKET ANALYSIS BY THERAPY
44. 6.44 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC CLASS
45. 6.45 ARGENTINA MARKET ANALYSIS BY THERAPY
46. 6.46 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC CLASS
47. 6.47 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPY
48. 6.48 MEA MARKET ANALYSIS
49. 6.49 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC CLASS
50. 6.50 GCC COUNTRIES MARKET ANALYSIS BY THERAPY
51. 6.51 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC CLASS
52. 6.52 SOUTH AFRICA MARKET ANALYSIS BY THERAPY
53. 6.53 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC CLASS
54. 6.54 REST OF MEA MARKET ANALYSIS BY THERAPY
55. 6.55 KEY BUYING CRITERIA OF HEALTHCARE
56. 6.56 RESEARCH PROCESS OF MRFR
57. 6.57 DRO ANALYSIS OF HEALTHCARE
58. 6.58 DRIVERS IMPACT ANALYSIS: HEALTHCARE
59. 6.59 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
60. 6.60 SUPPLY / VALUE CHAIN: HEALTHCARE
61. 6.61 HEALTHCARE, BY THERAPEUTIC CLASS, 2024 (% SHARE)
62. 6.62 HEALTHCARE, BY THERAPEUTIC CLASS, 2024 TO 2035 (USD Billion)
63. 6.63 HEALTHCARE, BY THERAPY, 2024 (% SHARE)
64. 6.64 HEALTHCARE, BY THERAPY, 2024 TO 2035 (USD Billion)
65. 6.65 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.2.2 BY THERAPY, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.3.2 BY THERAPY, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.4.2 BY THERAPY, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.5.2 BY THERAPY, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.6.2 BY THERAPY, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.7.2 BY THERAPY, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.8.2 BY THERAPY, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.9.2 BY THERAPY, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.10.2 BY THERAPY, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.11.2 BY THERAPY, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.12.2 BY THERAPY, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.13.2 BY THERAPY, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.14.2 BY THERAPY, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.15.2 BY THERAPY, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.16.2 BY THERAPY, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.17.2 BY THERAPY, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.18.2 BY THERAPY, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.19.2 BY THERAPY, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.20.2 BY THERAPY, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.21.2 BY THERAPY, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.22.2 BY THERAPY, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.23.2 BY THERAPY, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.24.2 BY THERAPY, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.25.2 BY THERAPY, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.26.2 BY THERAPY, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.27.2 BY THERAPY, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.28.2 BY THERAPY, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.29.2 BY THERAPY, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Billion)
  2. 7.30.2 BY THERAPY, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Benign Prostatic Hyperplasia Treatment Market Segmentation

Benign Prostatic Hyperplasia Treatment Market By Therapeutic Class (USD Billion, 2025-2035)

Alpha Blockers
5- Alpha Reductase Inhibitors
Phosphodiesterase-5 Inhibitors
Others

Benign Prostatic Hyperplasia Treatment Market By Therapy (USD Billion, 2025-2035)

Mono Drug Therapy
Combination Drug Therapy

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”